PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Sarad Pawar Naik Bukke

Victoria University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · JOURNAL ARTICLE

Translational advances in p53 targeted cancer therapy from molecular mechanisms to clinical application

Discover Oncology

A narrative review evaluating translational barriers to p53-targeted therapy, raising mechanistic questions and proposing future directions rather than reporting a new trial result or establishing clinical efficacy.

Hypothesis-GeneratingCancer Related Molecular Pathways M. Kasi Viswanadh Histone Deacetylase Inhibitors Research

Reported

Y220C prevalence in TP53-mutant t…approximately 1.8%

Rezatapopt objective response rat…33–34%

Rezatapopt median duration of res…6.2–7.6 months

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support